Abstract
The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized over the past two decades, bringing forth an era in which more than a dozen therapeutic agents are now available to treat patients. As a consequence, personalized care has become a critical part of developing effective treatment guidelines and improving patient outcomes. One of the most important emerging aspects of precision medicine in cancer is matching patients and treatments based on the genomic characteristics of an individual and their tumour. Despite the lack of a single genomic predictor of treatment response or prognostication feature in RCC, emerging research suggests that the identification of such markers remains promising. Mutations in VHL and alterations in its downstream pathways are the mainstay of RCC development and progression. However, the predictive value of VHL mutations has been questioned. Further research has examined mutations in genes involved in chromosome remodelling (for example, PBRM1, BAP1 and SETD2), DNA methylation and DNA damage repair, all of which have been associated with clinical outcomes. Here, we provide a comprehensive overview of genomic evidence in the context of RCC and its potential predictive and prognostic value.
Key points
Renal cell carcinoma (RCC) is a complex disease entity with different histological subtypes characterized by distinct clinical and pathophysiological features; genomic research has identified relevant alterations associated with each RCC subtype.
In the past two decades, new insights into the mechanisms that underlie the development and progression of RCC have expanded treatment options; genomic data might guide treatment choices by enabling individuals to be matched with therapeutics that specifically target the genomic and molecular alterations present in their tumours.
Despite a mechanistic link between VHL alterations and RCC, alterations in this driver gene are not clearly associated with clinical outcomes.
Growing evidence supports the prognostic value of chromatin remodelling genes, such as PBRM1 and BAP1; alterations in PBRM1 also seem to have predictive value in responses to immunotherapy.
Concerning non-clear cell RCC, investigations are underway to identify the clinical role of alterations in genes such as MET in papillary RCC, TERT, TP53 and PTEN in chromophobe RCC, NF2 in collecting duct RCC and EZH2 in medullary subtypes of RCC.
The unique genomic and clinical features of a patient have a complex effect on disease progression and responses to treatment — this variability must be addressed when assessing potential prognostic and predictive factors in RCC.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354–366 (2017).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991–5004 (2004).
Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994).
Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013).
Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313–326.e5 (2018).
Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Jonasch, E. NCCN guidelines updates: management of metastatic kidney cancer. J. Natl Compr. Canc. Netw. 17, 587–589 (2019).
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Seizinger, B. R. et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332, 268–269 (1988).
Frew, I. J. & Moch, H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu. Rev. Pathol. 10, 263–289 (2015).
Wallace, A. C. & Nairn, R. C. Renal tubular antigens in kidney tumors. Cancer 29, 977–981 (1972).
Lindgren, D., Sjolund, J. & Axelson, H. Tracing renal cell carcinomas back to the nephron. Trends Cancer 4, 472–484 (2018).
Gu, Y. F. et al. Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade. Cancer Discov. 7, 900–917 (2017).
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623.e17 (2018).
Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317–1320 (1993).
Iliopoulos, O. et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).
Wiesener, M. S. et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61, 5215–5222 (2001).
Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942–1948 (2000).
Yao, M. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569–1575 (2002).
Rini, B. I. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 98, 756–762 (2006).
Patard, J. J. et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 123, 395–400 (2008).
Kroeger, N. et al. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer 119, 1547–1554 (2013).
Kondo, K. et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34, 58–68 (2002).
Schraml, P. et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196, 186–193 (2002).
Gimenez-Bachs, J. M. et al. Determination of vhl gene mutations in sporadic renal cell carcinoma. Eur. Urol. 49, 1051–1057 (2006).
Choueiri, T. K. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860–865; discussion 865–866 (2008).
Choueiri, T. K. et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin. Cancer Res. 19, 5218–5226 (2013).
Smits, K. M. et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin. Cancer Res. 14, 782–787 (2008).
Kim, B. J. et al. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget 8, 13979–13985 (2017).
Reisman, D., Glaros, S. & Thompson, E. A. The SWI/SNF complex and cancer. Oncogene 28, 1653 (2009).
Kenneth, N. S. et al. SWI/SNF regulates the cellular response to hypoxia. J. Biol. Chem. 284, 4123–4131 (2009).
Hodges, C., Kirkland, J. G. & Crabtree, G. R. The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb. Perspect. Med. 6, a026930 (2016).
Thompson, M. Polybromo-1: the chromatin targeting subunit of the PBAF complex. Biochimie 91, 309–319 (2009).
Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).
Toma, M. I. et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10, 634–642 (2008).
Gao, W. et al. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma. Proc. Natl Acad. Sci. USA 114, 1027–1032 (2017).
Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751–759 (2012).
Hakimi, A. A. et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63, 848–854 (2013).
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Gossage, L. et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 53, 38–51 (2014).
Ho, T. H. et al. Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. Eur. Urol. Focus. 2, 204–209 (2016).
Fay, A. P. et al. Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. J. Natl Compr. Canc. Netw. 14, 820–824 (2016).
Hsieh, J. J. et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur. Urol. 71, 405–414 (2017).
Voss, M. H. et al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncol. 19, 1688–1698 (2018).
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
Hakimi, A. A. et al. The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB). J. Clin. Oncol. 37, 666–666 (2019).
Alaiwi, S. A. et al. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). J. Clin. Oncol. 37, 103–103 (2019).
Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44, 17–19 (2011).
Kapur, P. et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 14, 159–167 (2013).
Joseph, R. W. et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 120, 1059–1067 (2014).
Zisman, A. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559–4566 (2002).
Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259–3267 (2013).
Joseph, R. W. et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J. Urol. 195, 180–187 (2016).
Shrestha, R. et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 11, 8 (2019).
Yoh, S. M., Lucas, J. S. & Jones, K. A. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. Genes Dev. 22, 3422–3434 (2008).
Edmunds, J. W., Mahadevan, L. C. & Clayton, A. L. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 27, 406–420 (2008).
Gao, X. et al. Comprehensive genomic profiling of metastatic tumors in a phase 2 biomarker study of everolimus in advanced renal cell carcinoma. Clin. Genitourin. Cancer 16, 341–348 (2018).
Simon, J. M. et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. 24, 241–250 (2014).
Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363 (2010).
Tiedemann, R. L. et al. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. Oncotarget 7, 1927–1946 (2016).
Li, F. et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 153, 590–600 (2013).
Kanu, N. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 34, 5699–5708 (2015).
Pena-Llopis, S. et al. Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res. 73, 4173–4179 (2013).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Muller, J. et al. Histone methyltransferase activity of a drosophila polycomb group repressor complex. Cell 111, 197–208 (2002).
Yamaguchi, H. & Hung, M. C. Regulation and role of EZH2 in cancer. Cancer Res. Treat. 46, 209–222 (2014).
Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
Liu, L. et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 117, 351–362 (2016).
Wagener, N. et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int. J. Cancer 123, 1545–1550 (2008).
Wagener, N. et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010).
Lee, H. W. & Choe, M. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker. Pathol. Int. 62, 735–741 (2012).
Ho, T. H. et al. Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma. J. Clin. Oncol. 35, 3706–3713 (2017).
Adelaiye-Ogala, R. et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Res. 77, 6651–6666 (2017).
Italiano, A. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19, 649–659 (2018).
Agulnik, M. et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J. Clin. Oncol. 34, TPS11071 (2016).
Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685–1694 (2018).
Ged, Y. et al. Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts). J. Clin. Oncol. 37, 551 (2019).
Labriola, M. et al. Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 37, 589–589 (2019).
Pignot, G. et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 69, 230–235 (2007).
Klatte, T. et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin. Cancer Res. 15, 1162–1169 (2009).
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68–73 (1997).
Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 58, 1719–1722 (1998).
Linehan, W. M. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135–145 (2016).
Birchmeier, C. et al. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915–925 (2003).
Tovar, E. A. & Graveel, C. R. MET in human cancer: germline and somatic mutations. Ann. Transl. Med. 5, 205 (2017).
Danilkovitch-Miagkova, A. & Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109, 863–867 (2002).
Pal, S. K. et al. Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling. Eur. Urol. 73, 71–78 (2018).
Cancer Genome Atlas Research Network et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135–145 (2016).
Albiges, L. et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin. Cancer Res. 20, 3411–3421 (2014).
Choueiri, T. K. et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181–186 (2013).
Twardowski, P. W. et al. Parallel (randomized) phase II evaluation of tivantinib (ARQ197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107. Kidney Cancer 1, 123–132 (2017).
Choueiri, T. K. et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J. Clin. Oncol. 35, 2993–3001 (2017).
Martinez Chanza, N. et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 20, 581–590 (2019).
Schöffski P. et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur. J. Cancer 87, 147–63 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03091192 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02761057 (2020).
Amin, M. B. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 26, 281–291 (2002).
Zbar, B. et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol. Biomarkers Prev. 11, 393–400 (2002).
Volpe, A. et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 110, 76–83 (2012).
Stec, R. et al. Chromophobe renal cell cancer — review of the literature and potential methods of treating metastatic disease. J. Exp. Clin. Cancer Res. 28, 134 (2009).
Prasad, S. R. et al. Segmental disorders of the nephron: histopathological and imaging perspective. Br. J. Radiol. 80, 593–602 (2007).
Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330 (2014).
Casuscelli, J. et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2, e92688 (2017).
Shuch, B. et al. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 17, 46–54 (2012).
Cheville, J. C. et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am. J. Surg. Pathol. 28, 435–441 (2004).
Adibi, M. et al. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol. Oncol. 33, 427.e17–23 (2015).
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
Jones, T. D. et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 104, 1195–1203 (2005).
Pal, S. K. et al. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol. Cancer Res. 13, 130–137 (2015).
Voss, M. H. et al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann. Oncol. 25, 663–668 (2014).
Bi, M. et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc. Natl Acad. Sci. USA 113, 2170–2175 (2016).
Malouf, G. G. et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur. Urol. 70, 348–357 (2016).
Bakouny, Z. et al. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 37, 4514–4514 (2019).
Wang, Z. et al. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape. Clin. Cancer Res. 23, 6686–6696 (2017).
Sebastian, C., Artur, J. & Beata, S.-C. Collecting (Bellini) duct carcinoma: a clinical study of a rare tumour and review of the literature. Can. Urol. Assoc. J. 9, E589–E593 (2015).
Gupta, R. et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am. J. Surg. Pathol. 36, 1265–1278 (2012).
Pinto, A. et al. Collecting duct carcinoma of the kidney: analysis of our experience at the SPANISH ‘Grupo Centro’of genitourinary tumors. Kidney Cancer 3, 177–182 (2019).
Pécuchet, N. et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann. Oncol. 24, 2963–2967 (2013).
Malouf, G. G. et al. Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas. Sci. Rep. 6, 30988 (2016).
Pal, S. K. et al. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur. Urol. 70, 516–521 (2016).
Lopez-Lago, M. A. et al. Loss of the tumor suppressor gene NF2, encoding merlin constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 29, 4235–4249 (2009).
Ali, S. M. et al. Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation. Eur. Urol. 67, 1195–1196 (2015).
Ross, J. S. et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 122, 702–711 (2016).
Li, N. et al. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors. Eur. Rev. Med. Pharmacol. Sci. 23, 5874–5883 (2019).
Mathew Thomas, V., Bindal, P. & Vredenburgh, J. J. Everolimus and bevacizumab in the management of recurrent, progressive intracranial NF2 mutated meningioma. Case Rep. Oncol. 12, 126–130 (2019).
Goutagny, S. et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J. Neurooncol. 122, 313–320 (2015).
Tsaras, G. et al. Complications associated with sickle cell trait: a brief narrative review. Am. J. Med. 122, 507–512 (2009).
Shah, A. Y. et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 120, 782–792 (2017).
Tannir, N. M. et al. Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): a multicenter experience. J. Clin. Oncol. 29, 386–386 (2011).
Msaouel, P. et al. Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy. J. Clin. Oncol. 36, 4575–4575 (2018).
Cheng, J. X. et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod. Pathol. 21, 647–652 (2008).
Liu, Q. et al. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am. J. Surg. Pathol. 37, 368–374 (2013).
Calderaro, J. et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology 61, 428–435 (2012).
Beckermann, K. E. et al. Renal medullary carcinoma: establishing standards in practice. J. Oncol. Pract. 13, 414–421 (2017).
Marino-Enriquez, A. et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 50, 146–153 (2011).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02601950 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03587662 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03274258 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02721732 (2020).
Zhong, M. et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am. J. Surg. Pathol. 36, 654–662 (2012).
Cheng, X. et al. Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. BMC Urol. 16, 40 (2016).
Choueiri, T. K. et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116, 5219–5225 (2010).
Malouf, G. G. et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC network. Ann. Oncol. 21, 1834–1838 (2010).
Malouf, G. G. et al. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clin. Cancer Res. 22, 6236–6246 (2016).
Humphrey, P. A. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs — Part B: prostate and bladder tumours. Eur. Urol. 70, 106–119 (2016).
Argani, P. et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol. 159, 179–192 (2001).
Klatte, T. et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am. J. Clin. Pathol. 137, 761–768 (2012).
Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465–475 (2014).
Malouf, G. G. et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin. Cancer Res. 19, 4673–4684 (2013).
Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13–21 (2015).
Malouf, G. G. et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin. Cancer Res. 20, 4129–4140 (2014).
Network CGAR. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135–145 (2016).
Motzer, R. J. et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur. Urol. 73, 62–68 (2018).
Dizman, N. et al. Adjuvant treatment in renal cell carcinoma. Clin. Adv. Hematol. Oncol. 16, 555–563 (2018).
Escudier, B. J. et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): validation of the 16-gene recurrence score in stage III patients. J. Clin. Oncol. 35, 4508–4508 (2017).
Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008–2016 (2016).
Motzer, R. J. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). J. Clin. Oncol. 35, 4507–4507 (2017).
Gross-Goupil, M. et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann. Oncol. 29, 2371–2378 (2018).
Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649–1657 (2001).
Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97, 1663–1671 (2003).
Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002).
Patard, J. J. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22, 3316–3322 (2004).
Rini, B. et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 16, 676–685 (2015).
Rini, B. I. et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin. Cancer Res. 24, 4407–4415 (2018).
Brannon, A. R. et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152–163 (2010).
Brannon, A. R. et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol. 61, 258–268 (2012).
Brooks, S. A. et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77–84 (2014).
Zigeuner, R. et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur. Urol. 57, 102–109 (2010).
Morgan, T. M. et al. A multigene signature based on cell cycle proliferation improves prediction of mortality within 5 Yr of radical nephrectomy for renal cell carcinoma. Eur. Urol. 73, 763–769 (2018).
Karakiewicz, P. I. et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 25, 1316–1322 (2007).
Haake, S. M. et al. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol. Oncol. 34, 122.e1–122.e7 (2016).
Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404–2415 (2019).
Hakimi, A. A. et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III Trial. Cancer Discov. 9, 510–525 (2019).
Masiero, M. et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24, 229–241 (2013).
Choueiri, T. K. et al. Biomarker analyses from JAVELIN renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) [abstract 101]. J. Clin. Oncol. 37 (Suppl 15), 101 (2019).
Zhan, Y. et al. A five-gene signature predicts prognosis in patients with kidney renal clear cell carcinoma. Comput. Math. Methods Med. 2015, 842784 (2015).
Yao, M. et al. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int. J. Cancer 123, 1126–1132 (2008).
Boguslawska, J. et al. Expression of genes involved in cellular adhesion and extracellular matrix remodeling correlates with poor survival of patients with renal cancer. J. Urol. 195, 1892–1902 (2016).
Dai, J. et al. A four-gene signature predicts survival in clear-cell renal-cell carcinoma. Oncotarget 7, 82712–82726 (2016).
Xiong, Y. et al. Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients. Urol. Oncol. 38, 7.e1–7.e8 (2019).
Rebuzzi, S. E. et al. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev. Mol. Diagn. 20, 169–185 (2020).
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595–610.e11 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03226886 (2019).
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225 (2014).
Hahn, A. W. et al. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8, 33614 (2017).
Al-Qassab, U. et al. PNFBA-12 Liquid biopsy for renal cell carcinoma. J. Urol. 197, e913–e914 (2017).
Pal, S. K. et al. Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur. Urol. 72, 557–564 (2017).
Markowski, M. C. et al. The microbiome and genitourinary cancer: a collaborative review. Eur. Urol. 75, 637–646 (2019).
Routy, B. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Pal, S. K. et al. Stool bacteriomic profiling in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors. Clin. Cancer Res. 21, 5286–5293 (2015).
Helmink, B. A. et al. The microbiome, cancer, and cancer therapy. Nat. Med. 25, 377–388 (2019).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, wrote the manuscript, made substantial contributions to discussions of the content and reviewed or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
S.K.P. consults for Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas. N.D. and E.J.P. declare no competing interests.
Additional information
Peer review information
Nature Reviews Nephrology thanks A.A. Hakimi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Chromothripsis
-
The shattering of a chromosome and reassembly of its fragments in a different order and orientation.
- Loss of heterozygosity
-
A chromosomal event involving the loss of one allele of a gene or a chromosomal region.
- Fuhrman grade
-
A scoring system based on pathological appearance (that is, diameter, shape and characteristics of nuclei) of renal cell carcinoma cells.
- Rhabdoid pathological features
-
Pathological characteristics that may be present in RCC cells and include a large and prominent nucleus, and prominent eosinophilic inclusion bodies.
- Microsatellite instability
-
The tendency to accumulate abnormally high rates of mutations owing to defects in DNA mismatch repair.
- Nude mice
-
Laboratory mice with impaired T cell-mediated immunity due to the absence of a thymus.
- TNM stage
-
A cancer staging system based on tumour extent, nodal involvement and the presence of metastatic disease.
- Genomic hybridization studies
-
Genetic method used to analyse copy number variations.
- Spindle cells
-
Narrow and elongated, spindle-shaped cells that can be present in sarcoma.
- Adjuvant therapies
-
Cancer therapies used with the intention of avoiding disease recurrence after complete resection of a tumour.
- Neoadjuvant settings
-
Treatment settings in which a cancer therapeutic is given to a patient with the intention of decreasing tumour burden before definitive surgery.
- Allelic imbalance
-
Instance in which two alleles of a gene have different levels of expression.
Rights and permissions
About this article
Cite this article
Dizman, N., Philip, E.J. & Pal, S.K. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 16, 435–451 (2020). https://doi.org/10.1038/s41581-020-0301-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-020-0301-x
This article is cited by
-
Polygenic risk score model for renal cell carcinoma in the Korean population and relationship with lifestyle-associated factors
BMC Genomics (2024)
-
The role of RNA-modifying proteins in renal cell carcinoma
Cell Death & Disease (2024)
-
Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma
Discover Oncology (2024)
-
Circadian gene ARNTL initiates circGUCY1A2 transcription to suppress non-small cell lung cancer progression via miR-200c-3p/PTEN signaling
Journal of Experimental & Clinical Cancer Research (2023)
-
Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts
Molecular Cancer (2023)